Last $1.25 USD
Change Today +0.01 / 0.81%
Volume 175.8K
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

ekso bionics holdings inc (EKSO) Snapshot

Open
$1.24
Previous Close
$1.24
Day High
$1.28
Day Low
$1.24
52 Week High
02/24/14 - $8.22
52 Week Low
10/1/14 - $0.75
Market Cap
98.1M
Average Volume 10 Days
272.6K
EPS TTM
--
Shares Outstanding
78.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EKSO BIONICS HOLDINGS INC (EKSO)

ekso bionics holdings inc (EKSO) Related Bloomberg News

View More Bloomberg News

ekso bionics holdings inc (EKSO) Related Businessweek News

No Related Businessweek News Found

ekso bionics holdings inc (EKSO) Details

Ekso Bionics Holdings, Inc. designs, develops, and commercializes exoskeletons or wearable robots, which host a variety of applications in medical, military, industrial, and consumer markets in North America and Europe. It offers Ekso, a bionic suit or wearable robot, which helps individuals with lower-extremity weakness; paralysis; hemiparesis due neurological disease; or injuries, such as spinal cord injuries, stroke, multiple sclerosis, and Guilain Barre syndrome to stand up and walk with a natural, fully weight bearing gait. The company’s Ekso is used primarily in a clinic or rehabilitation setting, under the supervision of a physical therapist, or in limited cases, as part of an IRB study with a trained lay spotter. The company was founded in 2005 and is based in Richmond, California. It has Ekso centers in the United States, Canada, Czech Republic, Denmark, England, Estonia, Finland, Germany, Italy, Norway, Poland, the Russian Federation, Spain, Sweden, Turkey, South Africa, and Mexico. As of October 31, 2012, Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital, PA.

60 Employees
Last Reported Date: 06/24/14
Founded in 2005

ekso bionics holdings inc (EKSO) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $137.8K
Co-Founder, Chief Technology Officer and Pres...
Total Annual Compensation: $151.9K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $144.8K
Chief Operating Officer
Total Annual Compensation: $165.9K
Compensation as of Fiscal Year 2013.

ekso bionics holdings inc (EKSO) Key Developments

Ekso Bionics Holdings, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Ekso Bionics Holdings, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Ekso Bionics Holdings, Inc. Appoints Stanley Stern as an Independent Director of the Firm

Ekso Bionics Holdings, Inc. announced the appointment of Stanley Stern as an independent director of the firm, effective immediately. Mr. Stern currently is Managing Partner of Alnitak Capital, which he founded in 2013 to provide Board level strategic advisory services, primarily in technology related industries. Before founding Alnitak, Mr. Stern was a Managing Director at Oppenheimer & Co. from 1995-2000 and from 2004 to 2013, where, among other positions, he led the firm's investment banking department and technology investment banking groups. Prior to joining Oppenheimer & Co, Mr. Stern held roles at Salomon Brothers, STI Ventures and C.E. Unterberg.

Ekso Bionics Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Ekso Bionics Holdings, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of USD 1,588,183 against USD 833,764 a year ago. Loss from operations was USD 3,731,822 against USD 1,671,978 a year ago. Net income was USD 12,024,361 or USD 0.04 per diluted share against net loss of USD 1,893,924 or USD 0.09 per diluted share a year ago. For the six months, the company reported total revenue of USD 3,846,947 against USD 2,514,005 a year ago. Loss from operations was USD 11,934,623 against USD 7,537,809 a year ago. Net loss was USD 13,614,016 or USD 0.18 per diluted share against net loss of USD 9,090,634 or USD 0.43 per diluted share a year ago. Net cash used in operating activities was USD 12,295,164 against USD 6,761,753 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKSO:US $1.25 USD +0.01

EKSO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CYBERDYNE Inc ¥3,090 JPY -20.00
Parker-Hannifin Corp $122.76 USD +0.79
ReWalk Robotics Ltd $18.50 USD +0.34
Rex Bionics PLC 70.00 GBp 0.00
View Industry Companies
 

Industry Analysis

EKSO

Industry Average

Valuation EKSO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKSO BIONICS HOLDINGS INC, please visit www.eksobionics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.